^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Tab-cel (tabelecleucel)

i
Other names: ATA 129, ATA129, allogeneic EBV-specific CTLs ATA129, allogeneic EBV-specific cytotoxic T lymphocytes, EBV-CTLs, ATA-129
Associations
Company:
Atara, Pierre Fabre
Drug class:
Cytotoxic T lymphocyte stimulant, T-cell stimulant
Related drugs:
Associations
8d
Phase classification
|
Keytruda (pembrolizumab) • Tab-cel (tabelecleucel)
1m
Trial primary completion date • Post-transplantation
|
Rituxan (rituximab) • Tab-cel (tabelecleucel)
over1year
EBV Reactivation and Lymphomagenesis: More Questions than Answers. (PubMed, Curr Hematol Malig Rep)
These include immunosuppression reduction, nucleoside analogs, HDAC inhibitors, EBV-specific cytotoxic T-lymphocytes (CTLs), and monoclonal antibodies, such as rituximab. There is currently an open clinic trial combining the use of a HDAC inhibitor, nanatinostat, and ganciclovir to treat refractory/relapsed EBV lymphomas. Another novel therapy includes tabelecleucel, which is an allogenic EBV-directed T-cell immunotherapy that was approved by the European Medicines Agency, but is currently only available in the US for limited use in relapsed or refractory EBV-positive PTLD. Further research is needed to establish EBV monitoring protocols in high-risk populations, such as those with autoimmune disease, cancer, HIV, or receiving immunosuppressive therapy. Additionally, standardized treatments for both the prevention of EBV reactivation in high-risk populations and treatment of EBV reactivation and lymphoproliferation need to be established.
Review • Journal
|
Rituxan (rituximab) • Tab-cel (tabelecleucel) • nanatinostat (VRx-3996)
over1year
NEW AND UPDATED RESULTS FROM A MULTICENTER OPEN-LABEL GLOBAL PHASE3 STUDY OF TAB-CEL FOR EBV+PTLD FOLLOWING HCT OR SOT AFTER FAILURE OF RITUXIMAB OR RITUXIMAB+CHEMOTHERAPY (ALLELE) (EHA 2023)
Updated ALLELE P3 data, which included additional pts and longer follow-up, confirm that tab-cel providesconsistent clinically meaningful outcomes, including improved overall ORR, prolonged DOR and OS, and no safety concerns seen with other adoptive T-cell therapies, making it a potentially transformative treatment advance for r/r EBV + PTLD. EBV, Post-transplant lymphoproliferative disorder
Clinical • P3 data • IO biomarker
|
Rituxan (rituximab) • Tab-cel (tabelecleucel)
over3years
[VIRTUAL] COMPREHENSIVE ACTIVATION PROFILING OF TABELECLEUCEL, AN OFF-THE-SHELF, Allogeneic EBV-SPECIFIC T-CELL IMMUNOTHERAPY (ICML 2021)
The process for generating tab-cel from unrelated donors enriches for known EBV- specific clones and results in a net amplification of EBV-targeted T-cell clonality. Upon activation, tab-cel exhibits a multi-factorial activation profile and demonstrates PF associated with secretion of effector and chemoattractive cytokines. Altogether this multi-omics profiling will facilitate corollaries associated with clinical outcomes.
IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • CD69 (CD69 Molecule)
|
Tab-cel (tabelecleucel)
almost4years
ATA129-EBV-205: A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases (clinicaltrials.gov)
P2, N=228, Recruiting, Atara Biotherapeutics | Initiation date: Nov 2020 --> Feb 2021
Clinical • Trial initiation date
|
CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
|
Tab-cel (tabelecleucel)
almost4years
Clinical • New P2 trial
|
CD20 (Membrane Spanning 4-Domains A1) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule)
|
Tab-cel (tabelecleucel)
4years
[VIRTUAL] A Multicenter, Multicohort, Open-Label, Single-Arm per Cohort, Phase II Study to Assess the Efficacy and Safety of Tabelecleucel in Patients with EBV-Associated Diseases Using an Adaptive Two-Stage Study Design (ASH 2020)
A Phase III study of tab-cel for solid organ or allogeneic hematopoietic cell transplant patients with EBV+ PTLD after failure of rituximab or rituximab plus chemotherapy (NCT03394365) is ongoing. Figure 1. Study design schema
Clinical • P2 data • IO biomarker
|
CD8 (cluster of differentiation 8)
|
Rituxan (rituximab) • Tab-cel (tabelecleucel)